131875-08-6 Usage
Uses
Used in Pharmaceutical Industry:
Lexacalcitol is used as a therapeutic agent for the treatment of hyperparathyroidism and secondary hyperparathyroidism in patients with chronic kidney disease. It is utilized for its ability to decrease parathyroid hormone levels and reduce the release of calcium and phosphorus from bones, thereby maintaining normal blood mineral levels and preventing bone disorders.
Used in Chronic Kidney Disease Management:
Lexacalcitol is used as a medication to improve bone health in patients with chronic kidney disease. It is employed for its efficacy in lowering parathyroid hormone levels, which is crucial for managing the complications associated with this condition.
Check Digit Verification of cas no
The CAS Registry Mumber 131875-08-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,8,7 and 5 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 131875-08:
(8*1)+(7*3)+(6*1)+(5*8)+(4*7)+(3*5)+(2*0)+(1*8)=126
126 % 10 = 6
So 131875-08-6 is a valid CAS Registry Number.
InChI:InChI=1/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1
131875-08-6Relevant academic research and scientific papers
Highly potent cell differentiation-inducing analogues of 1α,25-dihydroxyvitamin D3: Synthesis and biological activity of 2-methyl-1,25-dihydroxyvitamin D3 with side-chain modifications
Fujishima, Toshie,Zhaopeng, Liu,Konno, Katsuhiro,Nakagawa, Kimie,Okano, Toshio,Yamaguchi, Kentaro,Takayama, Hiroaki
, p. 525 - 535 (2007/10/03)
Eight 2-methyl substituted analogues of 20-epi-22R-methyl-1α,25-dihydroxyvitamin D3 (5) and 20-epi-24,26,27-trihomo-22-oxa-1α,25-dihydroxyvitamin D3 (6: KH-1060) were convergently synthesized. Preparation of the CD-ring portions with modified side chains of 5 and 6, followed by palladium-catalyzed cross-coupling with the A-ring enyne synthons (20a-d), (3S,4S,5R)-, (3S,4R,5R)-, (3S,4S,5S)- and (3R,4R,5S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methyloct-1-en-7-yne, afforded two sets of four A-ring stereoisomers of 20-epi-2,22-dimethyl-1,25-dihydroxyvitamin D3 (7a-d) and 20-epi-24,26,27-trihomo-2-methyl-22-oxa-1,25-dihydroxyvitamin D3 (8a-d). The biological profiles of the hybrid analogues were assessed in terms of affinity for vitamin D receptor (VDR) and HL-60 cell differentiation-inducing activity in comparison with the natural hormone. The combined modifications of the A-ring at the 2-position and the side chain yielded analogues with high potency.
